Life Sciences is the next big thing to IT and that is happening to India now, Ranbaxy to develop anti-infective drugs for Merck...
India's Ranbaxy Laboratories Ltd. (Ranbaxy) is to develop new anti-infective drugs for Merck & Co Inc, (Merck) in a major deal underlining the growing use of Indian pharmaceutical research by multinational Companies.
Ranbaxy and Merck announced today that they have signed a strategic Product Development Agreement (the “Agreement”) providing for a drug discovery and clinical development collaboration for new products, in the anti-infective field. Potential Payments Totaling More than $100 Million .
Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.
The Indian group will get an undisclosed upfront sum and could receive more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.
hey,
ReplyDeleteYou have very well stated that clinical research is now being taken up in India seriously. I must say that still there are not many institutions offering a course on such a sensitive topic. ICRI is one of the premier institutes of the country and aims at promoting clinical research in the country. With foreign recognition and good faculty, its future prospects seem to b very bright. A number of clinical research projects have been taken up by ICRI and hav produced medicines of great value. It should b seriously considered by all aspirants of research very seriously. To apply for the the college just click on the url..http://tinyurl.com/6ellwe